AQSTNGMHealthcare·Drug Manufacturers - Specialty & Generic#38 in industry

Aquestive Therapeutics, Inc.

Reports in 15d· 2026-05-12

+18.2% · 90d

$4.10

+0.02 (+0.49%)

After-Hours $4.10(+0.00)

News

No News Yet

Press releases and SEC filings for AQST will appear here as they are published.

Check back later for updates

Key Data

Market Cap$500.4M

Open$4.06

Prev Close$4.08

Day Range$4.06 – $4.18

52W Range$2.12 – $7.55

Volume764,151

P/E (TTM)—

EPS$-0.78

Dividend Yield—

Beta1.53

Profit Margin-188.09%

Revenue Growth9.70%

Price Target$8.89(+116.8%)

Next Earnings2026-05-12(15d)

Analyst Ratings

Strong Buy9 analysts

Buy 9Hold 0Sell 0

About

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Healthcare · Drug Manufacturers - Specialty & Generic

147 employees

www.aquestive.com